Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 1.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 2,429,450 shares of the company's stock after selling 26,211 shares during the period. Janus Henderson Group PLC owned 2.62% of Crinetics Pharmaceuticals worth $124,131,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CRNX. California State Teachers Retirement System grew its position in shares of Crinetics Pharmaceuticals by 11.1% during the first quarter. California State Teachers Retirement System now owns 64,292 shares of the company's stock valued at $3,010,000 after purchasing an additional 6,421 shares in the last quarter. Comerica Bank purchased a new position in Crinetics Pharmaceuticals in the first quarter worth about $33,000. SG Americas Securities LLC grew its position in Crinetics Pharmaceuticals by 1,224.8% in the second quarter. SG Americas Securities LLC now owns 79,051 shares of the company's stock worth $3,541,000 after acquiring an additional 73,084 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Crinetics Pharmaceuticals by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 41,344 shares of the company's stock worth $1,852,000 after acquiring an additional 3,257 shares in the last quarter. Finally, Calamos Advisors LLC grew its position in Crinetics Pharmaceuticals by 46.0% in the second quarter. Calamos Advisors LLC now owns 42,336 shares of the company's stock worth $1,896,000 after acquiring an additional 13,336 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company's stock.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Dana Pizzuti sold 14,375 shares of the company's stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total value of $785,306.25. Following the completion of the transaction, the insider now owns 28,507 shares in the company, valued at approximately $1,557,337.41. This represents a 33.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jeff E. Knight sold 501 shares of the company's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.52, for a total transaction of $28,316.52. Following the completion of the transaction, the chief operating officer now owns 51,653 shares of the company's stock, valued at approximately $2,919,427.56. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,911 shares of company stock worth $2,144,675 over the last three months. Company insiders own 6.00% of the company's stock.

Crinetics Pharmaceuticals Price Performance

Shares of CRNX traded up $0.58 during trading hours on Thursday, reaching $57.69. 809,872 shares of the company traded hands, compared to its average volume of 773,625. Crinetics Pharmaceuticals, Inc. has a 12-month low of $32.56 and a 12-month high of $62.53. The business has a fifty day moving average price of $56.14 and a 200-day moving average price of $51.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.05). During the same quarter in the previous year, the firm earned ($1.01) EPS. On average, equities research analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, September 16th. Citigroup raised their price objective on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. HC Wainwright lifted their price target on shares of Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. JMP Securities reaffirmed a "market outperform" rating and set a $80.00 price target on shares of Crinetics Pharmaceuticals in a research note on Friday, September 27th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $73.00 price target (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $70.18.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.